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Inhaled corticosteroids (ICS) and to a lesser extent nasal steroids 
(NS) have undoubtedly revolutionised asthma therapy and improved 
quality of life in a cost-effective way. However, current evidence 
suggests that every asthmatic child on corticosteroids is at risk of 
hypothalamic-pituitary-adrenal axis suppression (HPAS). As most 
patients with this complication are asymptomatic, those most at risk 
should be screened. If screening is inconclusive, adrenal function 
testing should be performed. On the basis of its outcome the most 
appropriate management should be determined.
In a recently published approach to paediatric asthma 
management,[1] treatment modifications included a 3-day course 
of rescue oral corticosteroids, intermittent use of ICS, a single ICS 
dose in the morning if possible, and a more prominent role for 
non-steroid controller medication. All these measures will protect 
the hypothalamic-pituitary-adrenal axis from suppression. However, 
the article neither recommended screening for nor suggested any 
management of HPAS.
Whenever exogenous corticosteroids are prescribed, endogenous 
cortisol production is reduced. This ‘systemic effect’ is determined 
by the dose, delivery device, technique, adherence, body surface 
area, body mass index (BMI) and duration of therapy, the number of 
corticosteroids being used and their pharmacokinetic characteristics, 
and genetic and epigenetic factors.[2-4] Age and gender are not 
predictors, unless the dose has not been adjusted to body surface 
area.[5] At supraphysiological ICS doses, 50% of children can be 
expected to develop HPAS,[2] while at physiological doses (i.e. a 
cortisol production rate of 3.0 - 10.6 mg/m2)[6] dose and effect 
have an inverse relationship.[2] Hypocortisolaemia has even been 
described at physiological doses.[2,7,8] HPAS is usually seen in 
all children after 6 - 42 months of ICS therapy,[3] but has been 
observed as early as 2  months (EWZ, unpublished data, 2011). 
Under basal conditions no untoward effects will be apparent, 
because the decreased produc tion of cortisol is balanced by the 
supply of exogenous corticosteroids. In the long term, the adrenal 
glands may atrophy. During a stressful event such as an infection, 
injury, burn or surgical operation, or even an asthma exacerbation, 
demand for cortisol may outstrip its exogenous supply. The stress 
can precipitate an adrenal crisis, which may lead to death. When 
CYP3A4 enzyme inhibitors (antiretrovirals, antifungals, calcium-
channel blockers, certain antibiotics and antidepressants)[9] are 
coadministered, metabolism of corticosteroids is reduced, resulting 
in HPAS or Cushing’s syndrome.[10]
In order to make recommendations for diagnosis, screening and 
management of HPAS in asthmatic children, I have reviewed the 
existing literature and presented the quality of the evidence assessed 
in three tables. The Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach was used. It 
classifies the quality of the evidence as high, moderate, low or very 
low, with the recommendations being either strong or weak.[11] 
Management suggestions that could not be substantiated by evidence 
are labelled ‘ungraded best practice’.[12]
Diagnosis of HPAS
HPAS presents as a spectrum (Table 1). Adrenal crisis is the 
most devastating presentation, but occurs rarely.[13] Chronic adrenal 
insufficiency (CAI) is frequently overlooked owing to its nonspecific 
clinical features.[7] For these reasons it is essential to diagnose HPAS 
in its subclinical state. The overnight metyrapone test should be 
used to make the definitive diagnosis of HPAS.[14] If metyrapone 
is not available, the 0.5 µg/1.73 m2 adrenocorticotrophic hormone 
(ACTH) stimulation test is a good second choice, provided serum 
cortisol levels are measured at 10, 15, 20, 25, 30 and 35 minutes.[15] 
Clinicians utilising the ACTH stimulation test need to be aware of 
several pitfalls.[16] Interpretation of results is assay specific. In 2015, 
Roche launched its Elecsys Cortisol II assay. It is more specific than 
the older cortisol assay and shows lower cross-reactivity, generating 
cortisol levels that are ~30% lower.[17] The pass criterion for the test 
therefore has to be down-adjusted to 350 nmol/L (from 500 nmol/L). 
No adjustments need to be made for levels <250 nmol/L, because the 
old and new assays correlate well at lower levels.
Screening for HPAS
Screening for HPAS (Table 2) is problematic, because no useful 
screening test has been identified so far.[18] Measurement of early-
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morning salivary cortisone has been suggested,[19] but its routine use 
is premature because it has not been evaluated against a gold-standard 
adrenal function test. Its low positive predictive value would also 
argue against its use. Endocrinologists diagnose adrenal insufficiency 
when the 08h00 - 10h00 serum cortisol level is <138 mmol/L,[12,20,21] 
while a serum cortisol level of >350 nmol/L (as measured with the 
Elecsys Cortisol II assay) virtually excludes HPAS.[21] A 06h00 - 08h00 
serum cortisol level of <83 nmol/L to suggest HPAS would be ideal,[2] 
but may be impractical. There is no scientific basis for labelling a 
level >276 nmol/L as safe.[22] Given the poor performance of the 
serum cortisol screen, only patients at high risk should be screened. 
If the results are inconclusive, the patient should be referred to an 
endocrinologist for definitive testing.
In order to identify patients at high risk, meticulous attention 
should be paid to an individual asthma patient’s treatment, the 
corresponding doses and calculation of the total steroid dose, 
relating this to body surface area. In addition, cognisance needs to be 
taken of the child’s BMI, adherence to therapy and the ICS route of 
administration, as lung deposition, and hence dose, varies between 
devices.[1,3]
Table 2. Screening recommendations for subclinical HPAS 
Strength of recommendation/level of 
evidence
Patients at highest risk A. On a supraphysiological total steroid dose (ICS + NS),  
i.e. >10.6 mg HC equivalent/m2/d (>BUD 848 µg/m2/d or  
>FP 424 µg/m2/d given by MDI + spacer)
Strong/moderate
B. On a physiological total steroid dose (≤10.6 mg HC 
equivalent/m2/d)
On multiple steroids
 ICS + prednisone: daily, alternate-day or recurrent   
5-day courses <10 days apart
Strong/low
ICS + NS Strong/moderate
ICS + topical potent steroids* Strong/low
Adherent to ICS + NS therapy Strong/high
BMI z-score <0† Strong/moderate
On an enzyme inhibitor Strong/varies with inhibitor
Screening test interpretation Serum cortisol at 08h00 - 10h00
<138 nmol/L: hypocortisolaemia Weak/low
>350 nmol/L‡: normal axis Weak/low
 138 - 350 nmol/L: refer for metyrapone or  
0.5 µg/1.73 m2 ACTH stimulation test
Strong/moderate
Screening frequency If serum cortisol > 350 nmol/L, screen 6-monthly if  
steroid dose not reduced
Ungraded best practice
HPAS = hypothalamic-pituitary-adrenal axis suppression; ICS = inhaled corticosteroids; NS = nasal steroids; HC = hydrocortisone; BUD = budesonide; FP = fluticasone propionate;  
MDI = metered-dose inhaler; BMI = body mass index; ACTH = adrenocorticotrophic hormone.
*Clobetasol propionate, betamethasone valerate, hydrocortisone butyrate.
†BMI z-score 0 - 2 does not exclude HPAS, but <0 is more likely.
‡As measured by the Elecsys Cortisol II assay.
Table 1. Diagnostic features of HPAS




Adrenal crisis Hypoglycaemia* – depressed level 
of consciousness/coma, convulsions; 
nausea (hypotension, syncope, severe 
weakness, abdominal pain, vomiting, 
backache, hyponatraemia, hyperkalaemia, 
hypercalcaemia)†
Usually <138 nmol/L Strong/moderate
CAI Lassitude, weakness, dizziness, nausea, 
headache, poor growth, weight loss, 
(orthostatic hypotension)†
<138 nmol/L at 08h00 - 10h00 Weak/very low
Subclinical
Hypocortisolaemia Inability to respond appropriately to stress <138 nmol/L at 08h00 - 10h00 Weak/low
Failed adrenal function test‡ Inability to respond appropriately to stress 138 - 350 nmol/L§ at 08h00 - 10h00 Strong/moderate
HPAS = hypothalamic-pituitary-adrenal axis suppression; CAI = chronic adrenal insufficiency; ACTH = adrenocorticotrophic hormone.
*Hypoglycaemia is the most common presentation of adrenal crisis in the paediatric age group.
†These clinical/laboratory findings are classic features, but have not been described in case series.
‡Metyrapone or 0.5 µg/1.73 m2 ACTH stimulation test.
§As measured by the Elecsys Cortisol II assay.
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Management of HPAS
Management of adrenal crisis is life-saving (Table 3). Treatment 
modification (besides hydrocortisone) for CAI or subclinical HPAS 
is essentially the same. The aim of the intervention is to keep the 
total steroid dose well within the lower-normal physiological range. [2] 
Steroid-sparing controllers available include leukotriene receptor 
antagonists, long-acting beta-agonists, long-acting theophylline, 
tiotropium bromide, and the biological agents omalizumab, 
mepolizumab and dupilumab.[1,23] Early-morning dosing of inhaled 
and nasal budesonide, ciclesonide, mometasone, and fluticasone 
propionate and furoate should be prescribed whenever symptom 
control allows it, thereby ensuring that the early-morning surge of 
ACTH is not suppressed. These four drugs have minimal systemic 
absorption.[24] Should HPAS develop while on nasal beclomethasone 
or budesonide, nasal therapy should therefore be switched to one of 
the newer agents. However, beclomethasone is the preferred ICS/
NS for any child treated with an enzyme inhibitor in addition to a 
steroid, because it is not metabolised by cytochrome P450.[10] Rescue 
oral corticosteroids should never be given for more than 3 days[25] and 
should not be provided to parents to be used when necessary.
Treatment modification for HPAS has been found to be effective. [26] 
Even when ICS doses are not reduced, HPAS seems to resolve in 
some patients.[27] This may be due to poor adherence to therapy or an 
increase in airway diameter with age, resulting in better control with 
reduced ICS doses.
Conclusions
Any asthmatic child on corticosteroids may develop HPAS. In the 
absence of clinical features, serum cortisol should be used to screen 
those most at risk. Screening should start 6 months into therapy 
and include children on supraphysiological steroid doses, those on 
multiple steroids or enzyme inhibitors, and those adherent to therapy 
or who are thin. If screening is inconclusive, adrenal function testing 
should be performed by a paediatric endocrinologist. Appropriate 
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Adrenal crisis HC 2 mg/kg (50 - 100 mg/m2) IV bolus, followed by  
HC 2 mg/kg/d (50 - 100 mg/m2/d) IV divided 6-hourly 
Strong/moderate
For hypoglycaemia: 5 mL/kg of 10% DW IV at 3 mL/kg/h Ungraded best practice
If in shock, treat with normal saline (0.9%) 20 mL/kg  
(maximum 60 mL/kg within 1 hour)
Ungraded best practice
CAI HC orally at 8 mg/m2/d, ⅔ given in the morning, ⅓ 2 hours  
after lunch; continued for about 1 year until axis has recovered
Weak/low
Modify asthma therapy by reducing steroid load on the axis Weak/low
 Substitute lower ICS and NS dose by using steroid-sparing 
medication
If possible, prescribe single morning dose of ICS and NS
If possible, use newer-generation NS*
 Aim for a steroid load of HC ≤6 mg/m2/d (BUD 480 µg/m2/d 
or FP 240 µg/m2/d given by MDI + spacer)
Subclinical HPAS
Hypocortisolaemia As for CAI Ungraded best practice
Failed adrenal function test As for CAI, but omit HC Ungraded best practice
Sick-day management
Home management of illness with fever Ungraded best practice
>38°C Double HC replacement until recovery (usually 3 days)
>39°C Treble HC replacement until recovery (usually 3 days)
 Unable to tolerate oral therapy due to 
gastroenteritis or trauma
HC IM/SC given at a bolus dose of 50 mg for primary school 
age children and 100 mg for adolescents; continue IV/IM as for 
adrenal crisis or switch to oral regimen depending on clinical 
state
Ungraded best practice
Asthma exacerbation If prednisone is given, there is no need to give HC as well Ungraded best practice
Minor surgery Double or treble HC dose Ungraded best practice
 Major surgery, trauma or disease 
requiring intensive care
IV HC regimen as for adrenal crisis, but tapering rapidly and 
switching to oral regimen depending on clinical state
Ungraded best practice
Additional management Medic Alert bracelet Ungraded best practice
Educate family Ungraded best practice
HPAS = hypothalamic-pituitary-adrenal axis suppression; HC = hydrocortisone; IV = intravenous; DW = dextrose water; CAI = chronic adrenal insufficiency; 
ICS = inhaled corticosteroids; NS = nasal steroids; BUD = budesonide; FP = fluticasone propionate; MDI = metered-dose inhaler; IM = intramuscular; 
SC = subcutaneous.
*Fluticasone, ciclesonide, mometasone.
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